% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Albert:825208,
author = {Albert, N. L. and Weller, M. and Suchorska, B. and
Galldiks, Norbert and Soffietti, R. and Kim, M. M. and La
Fugére, C. and Pope, W. and Law, I. and Arbizu, J. and
Chamberlain, M. and Vogelbaum, M. A. and Ellingson, B. M.
and Tonn, J. C.},
title = {{R}esponse {A}ssessment in {N}euro-{O}ncology ({RANO})
{W}orking {G}roup and {E}uropean {A}ssociation for
{N}euro-{O}ncology ({EANO}): {R}ecommendations for the
{C}linical {U}se of {PET} {I}maging in {G}liomas},
journal = {Neuro-Oncology},
volume = {18},
number = {9},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {FZJ-2016-07679},
pages = {1199 - 1208},
year = {2016},
abstract = {This guideline provides recommendations for the use of PET
imaging in gliomas. The review examines established clinical
benefit in glioma patients of PET using glucose (18F-FDG)
and amino acid tracers (11C-MET, 18F-FET, and 18F-FDOPA). An
increasing number of studies have been published on PET
imaging in the setting of diagnosis, biopsy, and resection
as well radiotherapy planning, treatment monitoring, and
response assessment. Recommendations are based on evidence
generated from studies which validated PET findings by
histology or clinical course. This guideline emphasizes the
clinical value of PET imaging with superiority of amino acid
PET over glucose PET and provides a framework for the use of
PET to assist in the management of patients with gliomas.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000384005900008},
pubmed = {pmid:27106405},
doi = {10.1093/neuonc/now058},
url = {https://juser.fz-juelich.de/record/825208},
}